Company intelligence / Profile preview

Glycyx

San Francisco, California, United Statesglycyx.com ↗

Ownership: Private
Development stage: Other

Overview

Glycyx’s lead candidate, axelopran, is a peripherally restricted opioid antagonist designed to reverse opioid-induced immunosuppression without compromising pain relief. Preclinical and early clinical data show robust safety and efficacy in restoring immune function and enabling T-cell infiltration into tumors when used with immune checkpoint inhibitors. The company has completed CMC work and built clinical supply through Phase 3.

Therapeutic areas: Oncology
Modalities: Small moleculePeripherally restricted opioid antagonist
Industry: Biotech

Drug pipeline

1 asset

axelopran

Partnerships

No major pharmaceutical or biotech partnerships are publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Glycyx.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glycyx.

Explore the full profile